Stryker (NYSE:SYK) Stock Price Target Cut by TD Cowen

Key Points

• TD Cowen cut Stryker’s price target to $290 from $298 and maintained a “Hold” rating, while Canaccord also downgraded the stock to “Hold.”
• Stryker shares fell 6.5% to $291.56 after the company reported quarterly EPS of $3.52 and revenue of $6.52 billion, both below analyst expectations.
• Despite weaker guidance and concerns over joint-replacement demand and supply issues, analysts remain broadly positive, with a consensus “Moderate Buy” rating and average price target of $357.64.

Stryker (NYSE:SYK - Get Free Report) had its price objective cut by investment analysts at TD Cowen from $298.00 to $290.00 in a research note issued to investors on Friday, Benzinga reports. The brokerage currently has a "hold" rating on the medical technology company's stock. TD Cowen's price target points to a potential downside of 0.54% from the company's previous close.

Several other equities research analysts have also issued reports on the company. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Stryker in a research report on Thursday. Evercore set a $350.00 price objective on shares of Stryker in a research report on Monday, July 6th. Canaccord Genuity Group downgraded Stryker from a "buy" rating to a "hold" rating and dropped their price target for the company from $385.00 to $300.00 in a research report on Friday. Argus set a $370.00 target price on Stryker in a research note on Thursday, July 9th. Finally, Stifel Nicolaus lowered their price target on shares of Stryker from $360.00 to $330.00 and set a "buy" rating for the company in a research note on Wednesday, September 30th. Seventeen research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $357.64.

Stryker Trading Down 6.5%

Shares of Stryker stock traded down $20.19 on Friday, hitting $291.56. 6,437,128 shares of the company's stock traded hands, compared to its average volume of 2,467,420. The company has a market capitalization of $111.83 billion, a price-to-earnings ratio of 30.21, a price-to-earnings-growth ratio of 1.96 and a beta of 0.78. Stryker has a one year low of $267.00 and a one year high of $389.33. The company has a fifty day moving average of $293.56 and a two-hundred day moving average of $324.86. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33.

Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings data on Thursday, October 29th. The medical technology company reported $3.52 EPS for the quarter, missing analysts' consensus estimates of $3.55 by ($0.03). The firm had revenue of $6.52 billion during the quarter, compared to analyst estimates of $6.62 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The company's revenue was up 7.6% on a year-over-year basis. During the same period last year, the business posted $3.19 EPS. As a group, sell-side analysts expect that Stryker will post 14.93 earnings per share for the current year.

Insider Buying and Selling at Stryker

In other Stryker news, Director Ronda E. Stryker sold 300,000 shares of Stryker stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $335.90, for a total value of $100,770,000.00. Following the completion of the transaction, the director directly owned 2,301,375 shares of the company's stock, valued at $773,031,862.50. This trade represents a 11.53% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Dylan Crotty sold 441 shares of Stryker stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $328.61, for a total value of $144,917.01. Following the completion of the transaction, the insider owned 6,102 shares of the company's stock, valued at approximately $2,005,178.22. This represents a 6.74% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 351,267 shares of company stock valued at $118,197,701 in the last 90 days. Insiders own 4.60% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Community Bank & Trust Waco Texas raised its holdings in Stryker by 2.3% during the 2nd quarter. Community Bank & Trust Waco Texas now owns 1,395 shares of the medical technology company's stock worth $439,000 after buying an additional 31 shares during the period. Cornerstone Financial Management LLC raised its stake in shares of Stryker by 66.0% in the 2nd quarter. Cornerstone Financial Management LLC now owns 78 shares of the medical technology company's stock valued at $25,000 after acquiring an additional 31 shares in the last quarter. NWF Advisory Services Inc. lifted its stake in shares of Stryker by 2.3% in the second quarter. NWF Advisory Services Inc. now owns 1,472 shares of the medical technology company's stock worth $463,000 after buying an additional 33 shares during the last quarter. Harold Davidson & Associates Inc. grew its stake in Stryker by 0.4% in the 1st quarter. Harold Davidson & Associates Inc. now owns 8,668 shares of the medical technology company's stock valued at $2,848,000 after buying an additional 34 shares during the last quarter. Finally, Private Harbour Investment Management & Counsel LLC lifted its position in Stryker by 0.9% during the 2nd quarter. Private Harbour Investment Management & Counsel LLC now owns 3,927 shares of the medical technology company's stock worth $1,236,000 after acquiring an additional 34 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors.

More Stryker News

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Analysts remain broadly constructive despite lowering estimates. RBC, Barclays, Citizens JMP and BTIG reduced their price targets but maintained Outperform, Overweight, Market Outperform or Buy ratings, indicating potential upside from recent levels. RBC price target article
• Neutral Sentiment: Third-quarter revenue increased 7.6% year over year to $6.52 billion, while adjusted EPS rose to $3.52 from $3.19. Management highlighted strength in MedSurg, margin improvement and continued investment in robotic surgery, but those positives were overshadowed by weaker areas of the business. Stryker third-quarter results
• Negative Sentiment: Stryker missed Wall Street expectations, reporting $3.52 in EPS versus approximately $3.55–$3.56 expected and $6.52 billion in revenue versus about $6.62 billion expected. The company also cut its 2026 forecast to 6.5%–7.0% organic sales growth and $14.80–$14.90 in adjusted EPS, down from prior guidance of 8.3%–9.3% sales growth and $14.95–$15.10 EPS. Stryker earnings and revenue miss
• Negative Sentiment: Investors remain concerned that weaker joint-replacement demand, supply disruptions and a previously unresolved manufacturing issue affecting peripheral vascular products could pressure sales into 2027. The disclosure has prompted scrutiny of the company’s execution, particularly as a new CEO takes over. Stryker peripheral vascular problems
• Negative Sentiment: Canaccord downgraded Stryker from Buy to Hold and cut its price target from $385 to $300, reinforcing concerns that the guidance reduction reflects more than a temporary earnings setback. Canaccord Stryker rating

About Stryker

Stryker Corporation NYSE: SYK is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company's product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.